Chronic stable angina pectoris/cardiology Circulatory System Angina pectoris
Conditions
Interventions
Participating physicians receive a spiral folder including the complete documents for four patients with chronic stable angina pectoris who are to be treated routinely with Procoralan® . Data will be
at the beginning of treatment) data will be documented on:
1. Date of examination
2. Patient data (age, gender, height, weight)
3. Anamnesis (duration a
Sponsors
Servier Deutschland GmbH (Germany)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult patients, either sex, with chronic stable angina pectoris 2. who are to be routinely treated with Procoralan®, regarding the summary of product characteristics, either in combination or not with beta blocker medications.
Exclusion criteria
Exclusion criteria: All contraindications listed in summary of product characteristics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study aims at gaining information on efficacy and tolerance of Procoralan® treatment (as proven in clinical trials) either in combination or not with beta blockers in patients under daily routine medical procedures. Additional information is sought on the percentil distribution of patients who's heart rate is reduced to less than 70 bpm or who´s heart rate is reduced by at least 10 bpm (responder analysis). | — |
Secondary
| Measure | Time frame |
|---|---|
| Supplementary information is to be gained regarding: 1. Influence of Procoralan® therapy on angina pectoris symptoms and resting heart rate 2. On possible correlations between Procoralan® and various pre- and concomitant medications 3. On possible adverse drug reactions 3. On administration of Procoralan® in accordance to summary of product information and routine medical practice | — |
Countries
Germany
Outcome results
None listed